INS and type 1 diabetes mellitus: Inhibition of glucagon secretion may be involved in the efficacy of DPP-4 inhibitors for insulin-treated patients [6] and inhibition of glucagon secretion as a GLP-1 receptor agonist may be important in type 1 diabetes [15].